ArticleFrontiers in veterinary science2026
Retinoic acid inhibits the infection of porcine reproductive and respiratory syndrome virus.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Porcine reproductive and respiratory syndrome virus (PRRSV) is a major pathogen threatening the global swine industry, with existing vaccines failing to provide broad protection due to the high viral genetic variability and immune evasion capacity. Retinoic acid (RA), a vitamin A metabolite known for immunomodulatory functions, has been reported to enhance antiviral innate immunity and suppress excessive inflammation. However, whether RA affects PRRSV infection remains unclear. Methods: The antiviral efficacy of all-trans retinoic acid (ATRA), the major biologically active form of RA, against PRRSV infection was evaluated in both MARC-145 cells and primary porcine alveolar macrophages (PAMs). Furthermore, transcriptomic profiling was conducted to investigate the regulatory effects of ATRA on uninfected and PRRSV-infected PAMs. Results: ATRA significantly inhibited PRRSV infection and replication with minimal cytotoxicity. Transcriptomic profiling revealed that ATRA upregulated basal immune signaling and metabolic transport pathways while suppressing non-specific inflammatory activity in uninfected PAMs. Interestingly, comparative transcriptomics revealed that PRRSV infection led to hyperinflammatory responses and disrupted lipid homeostasis in PAMs, while ATRA treatment reversed these alterations. Discussion: Our findings elucidate that RA exerts antiviral effects against PRRSV through a dual mechanism of attenuating excessive inflammation and restoring cellular metabolic homeostasis, highlighting its potential as an immunomodulatory agent for viral infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.